The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin

Marine Drugs

Volumn 7, Issue 3, 2009, Pages 331-340

  Kasper, Bernd ^a   Schmitt, Thomas ^a   Wuchter, Patrick ^a   Dimitrakopoulou Strauss, Antonia ^b   Ho, Anthony D ^a   Egerer, Gerlinde ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Fluorodeoxyglucose; Positron emission tomography; RECIST; Soft tissue sarcoma; Trabectedin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRABECTEDIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SOFT TISSUE SARCOMA; UNSPECIFIED SIDE EFFECT;

EID: 70349500212     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md7030331     Document Type: Article

References (28)

1. Pisters, P. Staging and Prognosis. In American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas; Pollock, R.E., Ed.; BC Decker, Inc.: Hamilton, ON, Canada, 2002; pp. 80-88.
2. Standard-Options-Recommandations. In Sarcome des Tissus Mous et Ostéosarcomes; Arnette Blackwell: Paris, France, 1995; Vol.1. pp. 1-113.
3. Verweij, J.; Mouridsen, H.T.; Nielsen, O.S.; Woll, P.J.; Somers, R.; van Oosterom, A.T.; van Glabbeke, M.; Tursz, T. The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. Crit. Rev. Oncol. Hematol. 1995, 20, 193-201.
4. Frustaci, S.; de Paoli, A.; Bidoli, E. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003, 65, 80-84. (Pubitemid 37346738)
5. Grobmyer, S.R.; Maki, R.G.; Demetri, G.D.; Mazumdar, M.; Riedel, E.; Brennan, M.F.; Singer, S. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol. 2004, 15, 1667-1672. (Pubitemid 39562608)
6. Pisters, P.W.; Patel, S.R.; Varma, D.G.; Cheng, S.C.; Chen, N.P.; Nguyen, H.T.; Feig, B.W.; Pollack, A.; Pollock, R.E.; Benjamin, R.S. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J. Clin. Oncol. 1997, 15, 3481-3487.
7. Wendtner, C.M.; Abdel-Rahman, S.; Krych, M.; Baumert, J.; Lindner, L.H.; Baur, A.; Hiddemann, W.; Issels, R.D. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J. Clin. Oncol. 2002, 20, 3156-3164.
8. Strauss, L.G.; Conti, P.S. The applications of PET in clinical oncology. J. Nucl. Med. 1991, 32, 623-648.
9. Schulte, M.; Brecht-Krauss, D.; Heymer, B.; Guhlmann, A.; Hartwig, G.; Sarkar, M.R.; Diederichs, C.G.; Schultheiss, M.; Kotzerke, J.; Reske, S.N. Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible? Eur. J. Nucl. Med. 1999, 26, 599-605.
10. 18F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann. Surg. 2000, 231, 380-386.
11. Eary, J.F.; Mankoff, D.A. Tumor metabolic rates in sarcoma using FDG PET. J. Nucl. Med. 1998, 39, 250-254.
12. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J. Clin. Oncol. 2000, 18, 1689-1695.
13. Gretschel, S.; Moesta, K.T.; Hünerbein, M.; Lange, T.; Gebauer, B.; Stroszczinsk, C.; Bembenek, A.; Schlag, P.M. New concepts of staging in gastrointestinal tumors as a basis of diagnosis and multimodal therapy. Onkologie 2004, 27, 23-30. (Pubitemid 38338491)
14. 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J. Nucl. Med. 2004, 45, 1480-1487.
15. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur. J. Cancer. 2003, 39, 2012-2020.
16. Schuetze, S.M.; Rubin, B.P.; Vernon, C.; Hawkins, D.S.; Bruckner, J.D.; Conrad, E.U., 3rd; Eary, J.F. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005, 103, 339-348.
17. Schuetze, S.M. Utility of positron emission tomography in sarcomas. Curr. Opin. Oncol. 2006, 18, 369-373. (Pubitemid 44297249)
18. Verweij, J. Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas? J. Clin. Oncol. 2005, 24, 5420-5423. (Pubitemid 46300124)
19. Fayette, J.; Coquard, I.R.; Alberti, L.; Ranchère, D.; Boyle, H.; Blay, J.Y. ET-743: A novel agent with activity in soft-tissue sarcomas. Curr. Opin. Oncol. 2006, 18, 347-353. (Pubitemid 44297245)
20. Grosso, F.; Forni, C.; Frapolli, R.; Greco, A.; Gronchi, A.; Jimeno, J.; Mantovani, R.; D'Incalci, M.; Pilotti, S.; Casali, P.G. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. Proc. Am. Soc. Clin. Oncol. 2007, 25, 18S (abstract 10000).
21. Ryan, D.P.; Supko, J.G.; Eder, J.P.; Seiden, M.V.; Demetri, G.; Lynch, T.J.; Fischman, A.J.; Davis, J. Jimeno, J.; Clark, J.W. Phase I and pharmacokinetic study of ecteinascidin 743 administerd as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res. 2001, 7, 231-242.
22. Trojani, M.; Contesso, G.; Coindre, J.M.; Rouesse, J.; Bui, N.B.; de Mascarel, A.; Goussot, J.F.; David, M.; Bonichon, F.; Lagarde, C. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer. 1984, 33, 37-42.
23. Schwarzbach, M.H.; Hinz, U.; Dimitrakopoulou-Strauss, A.; Willeke, F.; Cardona, S.; Mechtersheimer, G.; Lehnert, T.; Strauss, L.G.; Herfarth, C.; Buchler, M.W. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann. Surg. 2005, 241, 286-294.
24. Burger, C.; Buck, A. Requirements and implementation of a flexible kinetic modelling tool. J. Nucl. Med. 1997, 38, 1818-1823.
25. Cheng, E.Y.; Froelich, J.W.; Manivel, J.C.; Weigel, B.J.; Skubitz, K.M. Correlation of FDG-PET with histologic response after neoadjuvant chemotherapy for soft tissue sarcomas. Proc. Am. Soc. Clin. Oncol. 2009, 25, 18S (abstract 10583).
26. 18F-FDG studies in patients with primary and recurrent soft tissue sarcomas: impact on diagnosis and correlation with grading. J. Nucl. Med. 2001, 42, 713-720.
27. Jager, P.L.; Gietema, J.A.; van der Graaf, W.T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl. Med. Commun. 2004, 25, 433-438.
28. Kasper, B.; Dietrich, S.; Dimitrakopoulou-Strauss, A.; Strauss, L.G.; Haberkorn, U.; Ho, A.D.; Egerer, G. Early prediction of therapy outcome in patients with high risk soft tissue sarcoma using positron emission tomography. Onkologie 2008, 31, 107-112. (Pubitemid 351348089)